Fig 1: MDA-MB-231 and BT549 cells complemented with XRCC1 resist to BBR. MDA-MB-231 and BT549 cells over-expressed PARP1 didn't exhibit resistance to BBR. After treatment with BBR for 24 h, MTT assay shows the MDA-MB-231 and BT549 cells complemented with XRCC1 resist to BBR compared with cells transfected with empty vector (A). MTT assay shows the over-expressed PARP1 did not help cancer cells to resist to BBR compared with cells transfected with empty vector (B). t Test, ***P < .001, **P < .01, *P < .05
Fig 2: Western analysis of cellular RAD51, XRCC1, PARP1 and ECRR1 expressions after treatment with BBR. Western results showed BBR obviously decreased the expressions of XRCC1 and ERCC1, slightly decreased RAD51, but had no effects on PARP1 (A). The western assays were repeated for three times, and the results were quantified (B). t Test, **P < .01, ***P < .001 as compared with the control
Supplier Page from Sino Biological, Inc. for Human PARP-1/PARP Gene ORF cDNA clone expression plasmid, N-His tag